Kevan C. Herold, MD

Kevan Herold

Deputy Director for Translational Science

Kevan C Herold, MD, Professor of Immunobiology, serves as YCCI’s Deputy Director for Translational Science, including the Translational Technologies and Resources and Novel Methodologies components of the Yale CTSA. His career has been centered on translational research, including basic and investigator-initiated clinical trials involving new immunological therapies for autoimmune Type 1 diabetes (T1D). The broad scope of his work makes him ideally suited to foster studies that involve application of basic science discoveries to the clinical setting. His research includes studies of immunologic tolerance and the pathogenesis of autoimmune diabetes and the development of strategies to induce beta cell recovery from immune destruction. In addition to working in standard murine models of T1D, Dr. Herold is using humanized mice to understand the human responses that lead to disease and the ways in which they can be modified by immune modulation. He has studied the effects of immune modulators in patients and uses animal models to improve therapeutics for testing in clinical trials. He performed metabolic studies that characterized the natural history of beta cell loss in T1D that form the basis for the design of current clinical trials. Dr. Herold was recruited to Yale in 2006 as part of a new initiative in Human Translational Immunology, which has as its major goal the application of new immunological findings to human disease. He is PI of the Yale Autoimmunity Center of Excellence and TrialNet sites, Co-PI of a JDRF Autoimmunity Center and a member of the steering committees of these consortia. He is also a member of the Steering Committee of the Immune Tolerance Network. He designed and carried out the initial clinical trials, sponsored by the NIH and JDRF, that showed efficacy of anti-CD3 mAb for treatment of T1D. He also is the PI of 3 NIH-sponsored clinical trials including an anti-CD3 mAb prevention trial for relatives at risk for T1D, and has been awarded the Excellence in Clinical Research Award from the JDRF.